Frederique VEGRAN

Dr. Frederique VEGRAN

INSERM U1231, Université de Bourgogne Franche Comté (UBFC), Dijon, France
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Pierre SonveauxPierre Sonveaux
Pierre Sonveaux
Frederique VEGRANFrederique VEGRAN
Frederique VEGRAN
TSThies Schroeder
Thies Schroeder
MWMelanie Christiane Wergin
Melanie Christiane Wergin
JVJulien Verrax
Julien Verrax
MDMark W. Dewhirst
Mark W. Dewhirst
Tumors contain oxygenated and hypoxic regions, so the tumor cell population is heterogeneous. Hypoxic tumor cells primarily use glucose for glycolytic energy production and release lactic acid, creating a lactate gradient that mirrors the oxygen gradient in the tumor. By contrast, oxygenated tumor cells have been thought to primarily use glucose for oxidative energy production. Although lactate is generally considered a waste product, we now show that it is a prominent substrate that fuels the oxidative metabolism of oxygenated tumor cells. There is therefore a symbiosis in which glycolytic and oxidative tumor cells mutually regulate their access to energy metabolites. We identified monocarboxylate transporter 1 (MCT1) as the prominent path for lactate uptake by a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabolism. Inhibiting MCT1 with α-cyano-4-hydroxycinnamate (CHC) or siRNA in these cells induced a switch from lactate-fueled respiration to glycolysis. A similar switch from lactate-fueled respiration to glycolysis by oxygenated tumor cells in both a mouse model of lung carcinoma and xenotransplanted human colorectal adenocarcinoma cells was observed after administration of CHC. This retarded tumor growth, as the hypoxic/glycolytic tumor cells died from glucose starvation, and rendered the remaining cells sensitive to irradiation. As MCT1 was found to be expressed by an array of primary human tumors, we suggest that MCT1 inhibition has clinical antitumor potential.

31 March 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
Frederique VEGRANFrederique VEGRAN
Frederique VEGRAN
RBRomain Boidot
Romain Boidot
CMCarine Michiels
Carine Michiels
Pierre SonveauxPierre Sonveaux
Pierre Sonveaux
Olivier FeronOlivier Feron
Olivier Feron
Lactate generated from pyruvate fuels production of intracellular NAD+ as an end result of the glycolytic process in tumors. Elevated lactate concentration represents a good indicator of the metabolic adaptation of tumors and is actually correlated to clinical outcome in a variety of human cancers. In this study, we investigated whether lactate could directly modulate the endothelial phenotype and thereby tumor vascular morphogenesis and perfusion. We found that lactate could enter endothelial cells through the monocarboxylate transporter MCT-1, trigger the phosphorylation/degradation of IκBα, and then stimulate an autocrine NF-κB/IL-8 (CXCL8) pathway driving cell migration and tube formation. These effects were prevented by 2-oxoglutarate and reactive oxygen species (ROS) inhibitors, pointing to a role for prolyl-hydroxylase and ROS in the integration of lactate signaling in endothelial cells. PHD2 silencing in endothelial cells recapitulated the proangiogenic effects of lactate, whereas a blocking IL-8 antibody or IL-8–targeting siRNA prevented them. Finally, we documented in mouse xenograft models of human colorectal and breast cancer that lactate release from tumor cells through the MCT4 (and not MCT1) transporter is sufficient to stimulate IL-8–dependent angiogenesis and tumor growth. In conclusion, our findings establish a signaling role for lactate in endothelial cells and they identify the lactate/NF-κB/IL-8 pathway as an important link between tumor metabolism and angiogenesis. Cancer Res; 71(7); 2550–60. ©2011 AACR.

2 December 2012 in Nature Medicine
Verified
Journal Article
Closed access
Mélanie BruchardMélanie Bruchard
Mélanie Bruchard
GMGrégoire Mignot
Grégoire Mignot
VDValentin Derangère
Valentin Derangère
FCFanny Chalmin
Fanny Chalmin
ACAngélique Chevriaux
Angélique Chevriaux
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François

13 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Pierre SonveauxPierre Sonveaux
Pierre Sonveaux
TCTamara Copetti
Tamara Copetti
CSChristophe J De Saedeleer
Christophe J De Saedeleer
Frederique VEGRANFrederique VEGRAN
Frederique VEGRAN
JVJulien Verrax
Julien Verrax
Olivier FeronOlivier Feron
Olivier Feron
Switching to a glycolytic metabolism is a rapid adaptation of tumor cells to hypoxia. Although this metabolic conversion may primarily represent a rescue pathway to meet the bioenergetic and biosynthetic demands of proliferating tumor cells, it also creates a gradient of lactate that mirrors the gradient of oxygen in tumors. More than a metabolic waste, the lactate anion is known to participate to cancer aggressiveness, in part through activation of the hypoxia-inducible factor-1 (HIF-1) pathway in tumor cells. Whether lactate may also directly favor HIF-1 activation in endothelial cells (ECs) thereby offering a new druggable option to block angiogenesis is however an unanswered question. In this study, we therefore focused on the role in ECs of monocarboxylate transporter 1 (MCT1) that we previously identified to be the main facilitator of lactate uptake in cancer cells. We found that blockade of lactate influx into ECs led to inhibition of HIF-1-dependent angiogenesis. Our demonstration is based on the unprecedented characterization of lactate-induced HIF-1 activation in normoxic ECs and the consecutive increase in vascular endothelial growth factor receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF) expression. Furthermore, using a variety of functional assays including endothelial cell migration and tubulogenesis together with in vivo imaging of tumor angiogenesis through intravital microscopy and immunohistochemistry, we documented that MCT1 blockers could act as bona fide HIF-1 inhibitors leading to anti-angiogenic effects. Together with the previous demonstration of MCT1 being a key regulator of lactate exchange between tumor cells, the current study identifies MCT1 inhibition as a therapeutic modality combining antimetabolic and anti-angiogenic activities.

22 June 2015 in Nature Immunology
Verified
Journal Article
Closed access
Mélanie BruchardMélanie Bruchard
Mélanie Bruchard
CRCédric REBE
Cédric REBE
VDValentin Derangère
Valentin Derangère
DTDieudonnée Togbé
Dieudonnée Togbé
BRBernhard Ryffel
Bernhard Ryffel
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François

1 March 2012 in Immunity
Verified
Journal Article
Closed access
FCFanny Chalmin
Fanny Chalmin
GMGrégoire Mignot
Grégoire Mignot
Mélanie BruchardMélanie Bruchard
Mélanie Bruchard
ACAngélique Chevriaux
Angélique Chevriaux
Frederique VEGRANFrederique VEGRAN
Frederique VEGRAN
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François